

Mãjrtã Pã©ntek

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2220478/publications.pdf>

Version: 2024-02-01

130
papers

2,861
citations

159525

30
h-index

254106

43
g-index

148
all docs

148
docs citations

148
times ranked

3196
citing authors

#	ARTICLE	IF	CITATIONS
1	Alopecia areata and health-related quality of life: a systematic review and meta-analysis. <i>British Journal of Dermatology</i> , 2016, 175, 561-571.	1.4	144
2	Budget impact analysis of biosimilar infliximab (CT-P13) for the treatment of rheumatoid arthritis in six Central and Eastern European countries. <i>European Journal of Health Economics</i> , 2014, 15, 65-71.	1.4	108
3	EQ-5D in Central and Eastern Europe: 2000–2015. <i>Quality of Life Research</i> , 2016, 25, 2693-2710.	1.5	103
4	Biosimilars for the management of rheumatoid arthritis: economic considerations. <i>Expert Review of Clinical Immunology</i> , 2015, 11, 43-52.	1.3	83
5	Biological therapy in inflammatory bowel diseases: Access in Central and Eastern Europe. <i>World Journal of Gastroenterology</i> , 2015, 21, 1728.	1.4	64
6	Epidemiology of osteoporosis related fractures in Hungary from the nationwide health insurance database, 1999–2003. <i>Osteoporosis International</i> , 2008, 19, 243-249.	1.3	60
7	Exploring the relationship between EQ-5D, DLQI and PASI, and mapping EQ-5D utilities: a cross-sectional study in psoriasis from Hungary. <i>European Journal of Health Economics</i> , 2014, 15, 111-119.	1.4	60
8	Social/economic costs and health-related quality of life in patients with Duchenne muscular dystrophy in Europe. <i>European Journal of Health Economics</i> , 2016, 17, 19-29.	1.4	59
9	Parallel Valuation of the EQ-5D-3L and EQ-5D-5L by Time Trade-Off in Hungary. <i>Value in Health</i> , 2020, 23, 1235-1245.	0.1	58
10	Measurement properties of the EQ-5D-5L compared to the EQ-5D-3L in psoriasis patients. <i>Quality of Life Research</i> , 2017, 26, 3409-3419.	1.5	51
11	Psychometric properties of the Hungarian version of the eHealth Literacy Scale. <i>European Journal of Health Economics</i> , 2019, 20, 57-69.	1.4	49
12	State of the Art in Adoption of Contact Tracing Apps and Recommendations Regarding Privacy Protection and Public Health: Systematic Review. <i>JMIR MHealth and UHealth</i> , 2021, 9, e23250.	1.8	48
13	Cost-of-illness of patients with systemic sclerosis in a tertiary care centre. <i>Rheumatology</i> , 2010, 49, 1920-1928.	0.9	47
14	Comparison of the Psoriatic Arthritis Quality of Life (PsAQoL) questionnaire, the functional status (HAQ) and utility (EQ-5D) measures in psoriatic arthritis: results from a cross-sectional survey. <i>Scandinavian Journal of Rheumatology</i> , 2010, 39, 303-309.	0.6	45
15	A budget impact model for biosimilar infliximab in Crohn's disease in Bulgaria, the Czech Republic, Hungary, Poland, Romania, and Slovakia. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2016, 16, 1-7.	0.7	44
16	Proposal of a new scoring formula for the Dermatology Life Quality Index in psoriasis. <i>British Journal of Dermatology</i> , 2018, 179, 1102-1108.	1.4	42
17	Use of biologics for psoriasis in Central and Eastern European countries. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2015, 29, 2222-2230.	1.3	41
18	Social/economic costs and health-related quality of life of mucopolysaccharidosis patients and their caregivers in Europe. <i>European Journal of Health Economics</i> , 2016, 17, 89-98.	1.4	41

#	ARTICLE	IF	CITATIONS
19	Assessment of skin involvement in systemic sclerosis. <i>Rheumatology</i> , 2017, 56, v53-v66.	0.9	41
20	Validity of the EQ-5D-5L and EQ-5D-3L in patients with Crohn's disease. <i>Quality of Life Research</i> , 2019, 28, 141-152.	1.5	41
21	Social/economic costs and health-related quality of life in patients with juvenile idiopathic arthritis in Europe. <i>European Journal of Health Economics</i> , 2016, 17, 79-87.	1.4	40
22	A detailed analysis of "not relevant" responses on the <sc>DLQI</sc> in psoriasis: potential biases in treatment decisions. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2018, 32, 783-790.	1.3	40
23	Delphi approach to select rare diseases for a European representative survey. The BURQOL-RD study. <i>Health Policy</i> , 2012, 108, 19-26.	1.4	38
24	Social/economic costs and health-related quality of life in patients with cystic fibrosis in Europe. <i>European Journal of Health Economics</i> , 2016, 17, 7-18.	1.4	38
25	Disease burden of psoriatic arthritis compared to rheumatoid arthritis, Hungarian experiment. <i>Rheumatology International</i> , 2009, 30, 199-205.	1.5	36
26	Access to biologicals in Crohn's disease in ten European countries. <i>World Journal of Gastroenterology</i> , 2017, 23, 6294.	1.4	35
27	Biosimilars for the Management of Inflammatory Bowel Diseases: Economic Considerations. <i>Current Medicinal Chemistry</i> , 2019, 26, 259-269.	1.2	34
28	Biological therapy in inflammatory rheumatic diseases: issues in Central and Eastern European countries. <i>European Journal of Health Economics</i> , 2014, 15, 35-43.	1.4	33
29	Economic considerations and patients' preferences affect treatment selection for patients with rheumatoid arthritis: a discrete choice experiment among European rheumatologists. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 126-132.	0.5	33
30	Quality of Life and Costs in Parkinson's Disease: A Cross Sectional Study in Hungary. <i>PLoS ONE</i> , 2014, 9, e107704.	1.1	31
31	Costs of dementia in Hungary. <i>Journal of Nutrition, Health and Aging</i> , 2010, 14, 633-639.	1.5	30
32	Treatment preferences of originator versus biosimilar drugs in Crohn's disease; discrete choice experiment among gastroenterologists. <i>Scandinavian Journal of Gastroenterology</i> , 2016, 51, 22-27.	0.6	30
33	Bleeding out the quality-adjusted life years: evaluating the burden of primary dysmenorrhea using time trade-off and willingness-to-pay methods. <i>Pain</i> , 2017, 158, 2259-2267.	2.0	30
34	Social/economic costs and health-related quality of life in patients with scleroderma in Europe. <i>European Journal of Health Economics</i> , 2016, 17, 109-117.	1.4	28
35	Health economics and health technology assessment in Central and Eastern Europe: a dose of reality. <i>European Journal of Health Economics</i> , 2012, 13, 525-531.	1.4	27
36	Comparative efficacy and safety of biosimilar infliximab and other biological treatments in ankylosing spondylitis: systematic literature review and meta-analysis. <i>European Journal of Health Economics</i> , 2014, 15, 45-52.	1.4	27

#	ARTICLE	IF	CITATIONS
37	Validity of the EQ-5D in patients with pemphigus vulgaris and pemphigus foliaceus. <i>British Journal of Dermatology</i> , 2019, 180, 802-809.	1.4	27
38	Costs of rheumatoid arthritis in Hungary. <i>Journal of Rheumatology</i> , 2007, 34, 1437.	1.0	27
39	Efficacy and safety of infliximab-biosimilar compared to other biological drugs in rheumatoid arthritis: a mixed treatment comparison. <i>European Journal of Health Economics</i> , 2014, 15, 53-64.	1.4	26
40	Validity and reliability of the 9-item Shared Decision Making Questionnaire (SDM-Q-9) in a national survey in Hungary. <i>European Journal of Health Economics</i> , 2019, 20, 43-55.	1.4	25
41	DLQI scoring improves the discriminatory power of the Dermatology Life Quality Index in patients with psoriasis, pemphigus and morphea. <i>British Journal of Dermatology</i> , 2020, 182, 1167-1175.	1.4	25
42	Validity of EQ-5D, Skindex-16, DLQI and DLQI in patients with hidradenitis suppurativa. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, 2584-2592.	1.3	25
43	History of health technology assessment in Hungary. <i>International Journal of Technology Assessment in Health Care</i> , 2009, 25, 120-126.	0.2	24
44	Subjective expectations regarding length and health-related quality of life in Hungary: results from an empirical investigation. <i>Health Expectations</i> , 2014, 17, 696-709.	1.1	24
45	Health-related quality of life and its determinants in pemphigus: a systematic review and meta-analysis. <i>British Journal of Dermatology</i> , 2015, 173, 1076-1080.	1.4	24
46	Is the DLQI appropriate for medical decision-making in psoriasis patients?. <i>Archives of Dermatological Research</i> , 2018, 310, 47-55.	1.1	24
47	Cost-of-illness studies in nine Central and Eastern European countries. <i>European Journal of Health Economics</i> , 2019, 20, 155-172.	1.4	23
48	Cost-utility of biological treatment sequences for luminal Crohn's disease in Europe. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2017, 17, 597-606.	0.7	22
49	The burden of informal caregiving in Hungary, Poland and Slovenia: results from national representative surveys. <i>European Journal of Health Economics</i> , 2019, 20, 5-16.	1.4	22
50	Moderate to severe psoriasis patients' subjective future expectations regarding health-related quality of life and longevity. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2015, 29, 1398-1405.	1.3	21
51	Patients' access to biological therapy in chronic inflammatory conditions; per capita GDP does not explain the intercountry differences. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 942-943.	0.5	21
52	Musculoskeletal Involvement in Systemic Sclerosis: An Unexplored Aspect of the Disease. <i>Journal of Scleroderma and Related Disorders</i> , 2017, 2, 19-32.	1.0	21
53	Subjective health expectations at biological therapy initiation: a survey of rheumatoid arthritis patients and rheumatologists. <i>European Journal of Health Economics</i> , 2014, 15, 83-92.	1.4	20
54	Cost-effectiveness of biological treatment sequences for fistulising Crohn's disease across Europe. <i>United European Gastroenterology Journal</i> , 2018, 6, 310-321.	1.6	20

#	ARTICLE	IF	CITATIONS
55	Long-term efficacy and cost-effectiveness of infliximab as first-line treatment in rheumatoid arthritis: systematic review and meta-analysis. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2019, 19, 537-549.	0.7	19
56	Time to revise the Dermatology Life Quality Index scoring in psoriasis treatment guidelines. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019, 33, e267-e269.	1.3	19
57	Assessment of cognitive function in female rheumatoid arthritis patients: associations with cerebrovascular pathology, depression and anxiety. <i>Rheumatology International</i> , 2020, 40, 529-540.	1.5	19
58	EQ-5D studies in cardiovascular diseases in eight Central and Eastern European countries: a systematic review of the literature. <i>Kardiologia Polska</i> , 2018, 76, 860-870.	0.3	19
59	Health Related Quality of Life in Patients with Bladder Cancer: A Cross-Sectional Survey and Validation Study of the Hungarian Version of the Bladder Cancer Index. <i>Pathology and Oncology Research</i> , 2015, 21, 619-627.	0.9	17
60	Subjective health expectations of patients with age-related macular degeneration treated with antiVEGF drugs. <i>BMC Geriatrics</i> , 2017, 17, 233.	1.1	17
61	Unmet medical needs in ambulatory care in Hungary: forgone visits and medications from a representative population survey. <i>European Journal of Health Economics</i> , 2019, 20, 71-78.	1.4	17
62	A comparison of European, Polish, Slovenian and British EQ-5D-3L value sets using a Hungarian sample of 18 chronic diseases. <i>European Journal of Health Economics</i> , 2019, 20, 119-132.	1.4	17
63	Outcomes of Digital Biomarker-Based Interventions: Protocol for a Systematic Review of Systematic Reviews. <i>JMIR Research Protocols</i> , 2021, 10, e28204.	0.5	17
64	Exploring eHealth Literacy and Patient-Reported Experiences With Outpatient Care in the Hungarian General Adult Population: Cross-Sectional Study. <i>Journal of Medical Internet Research</i> , 2020, 22, e19013.	2.1	17
65	Social/economic costs and health-related quality of life in patients with histiocytosis in Europe. <i>European Journal of Health Economics</i> , 2016, 17, 67-78.	1.4	16
66	Discrepancies between the Dermatology Life Quality Index and utility scores. <i>Quality of Life Research</i> , 2016, 25, 1687-1696.	1.5	16
67	Valuation of pemphigus vulgaris and pemphigus foliaceus health states: a convenience sample experiment. <i>British Journal of Dermatology</i> , 2016, 175, 593-599.	1.4	15
68	Determinants of biological drug survival in rheumatoid arthritis: evidence from a Hungarian rheumatology center over 8 years of retrospective data. <i>ClinicoEconomics and Outcomes Research</i> , 2017, Volume 9, 139-147.	0.7	15
69	Transferability of results of cost utility analyses for biologicals in inflammatory conditions for Central and Eastern European countries. <i>European Journal of Health Economics</i> , 2014, 15, 27-34.	1.4	14
70	The Economic Impact of Biosimilars on Chronic Immune-Mediated Inflammatory Diseases. <i>Current Pharmaceutical Design</i> , 2018, 23, 6770-6778.	0.9	14
71	New insights into the burden and costs of multiple sclerosis in Europe: Results for Hungary. <i>Multiple Sclerosis Journal</i> , 2017, 23, 91-103.	1.4	13
72	Capability of well-being: validation of the Hungarian version of the ICECAP-A and ICECAP-O questionnaires and population normative data. <i>Quality of Life Research</i> , 2020, 29, 2863-2874.	1.5	13

#	ARTICLE	IF	CITATIONS
73	Resource utilization, work productivity and costs in patients with hidradenitis suppurativa: a cost-of-illness study. Expert Review of Pharmacoeconomics and Outcomes Research, 2022, 22, 399-408.	0.7	13
74	EULAR Points to Consider (PtC) for designing, analysing and reporting of studies with work participation as an outcome domain in patients with inflammatory arthritis. Annals of the Rheumatic Diseases, 2021, 80, 1116-1123.	0.5	13
75	Acceptability of less than perfect health states in rheumatoid arthritis: the patients' perspective. European Journal of Health Economics, 2014, 15, 73-82.	1.4	12
76	Towards a Central-Eastern European EQ-5D-3L population norm: comparing data from Hungarian, Polish and Slovenian population studies. European Journal of Health Economics, 2019, 20, 141-154.	1.4	12
77	Perceived Risks Contra Benefits of Using Biosimilar Drugs in Ulcerative Colitis: Discrete Choice Experiment among Gastroenterologists. Value in Health Regional Issues, 2016, 10, 85-90.	0.5	11
78	Subjective expectations regarding ageing: a cross-sectional online population survey in Hungary. European Journal of Health Economics, 2019, 20, 17-30.	1.4	11
79	EULAR/eumusc.net standards of care for rheumatoid arthritis: cross-sectional analyses of importance, level of implementation and care gaps experienced by patients and rheumatologists across 35 European countries. Annals of the Rheumatic Diseases, 2020, 79, 1423-1431.	0.5	11
80	Patient experiences with outpatient care in Hungary: results of an online population survey. European Journal of Health Economics, 2019, 20, 79-90.	1.4	10
81	EQ-5D studies in musculoskeletal and connective tissue diseases in eight Central and Eastern European countries: a systematic literature review and meta-analysis. Rheumatology International, 2017, 37, 1957-1977.	1.5	9
82	Disease burden of patients with pemphigus from a societal perspective. Expert Review of Pharmacoeconomics and Outcomes Research, 2021, 21, 77-86.	0.7	9
83	Disease-Related Costs Published in The Middle East and North Africa Region: Systematic Review and Analysis of Transferability. Pharmacoeconomics, 2022, 40, 587-599.	1.7	9
84	EQ-5D studies in nervous system diseases in eight Central and East European countries: a systematic literature review. European Journal of Health Economics, 2019, 20, 109-117.	1.4	8
85	Did You Get What You Wanted? Patient Satisfaction and Congruence Between Preferred and Perceived Roles in Medical Decision Making in a Hungarian National Survey. Value in Health Regional Issues, 2020, 22, 61-67.	0.5	8
86	Predicting Patient-Level 3-Level Version of EQ-5D Index Scores From a Large International Database Using Machine Learning and Regression Methods. Value in Health, 2022, 25, 1590-1601.	0.1	8
87	HTA in Central and Eastern European countries; the 2001: A Space Odyssey and efficiency gain. European Journal of Health Economics, 2014, 15, 675-680.	1.4	7
88	Patients with rheumatoid arthritis facing sick leave or work disability meet varying regulations: a study among rheumatologists and patients from 44 European countries. Annals of the Rheumatic Diseases, 2019, 78, 1472-1479.	0.5	7
89	Patient-assigned health utility values for controlled and uncontrolled pemphigus vulgaris and foliaceus. Journal of the European Academy of Dermatology and Venereology, 2019, 33, 2106-2113.	1.3	7
90	Subjective well-being in patients with pemphigus: a path analysis. European Journal of Health Economics, 2019, 20, 101-107.	1.4	7

#	ARTICLE	IF	CITATIONS
91	Long-Term Efficacy of Tumor Necrosis Factor Inhibitors for the Treatment of Methotrexate-Naive Rheumatoid Arthritis: Systematic Literature Review and Meta-Analysis. <i>Advances in Therapy</i> , 2019, 36, 721-745.	1.3	7
92	Dermatology Life Quality Index (DLQI) score bands are applicable to DLQI-Relevant (DLQI-R) scoring. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, e484-e486.	1.3	7
93	Validation of the PAM-13 instrument in the Hungarian general population 40 years old and above. <i>European Journal of Health Economics</i> , 2022, 23, 1341-1355.	1.4	7
94	Health status and costs of ambulatory patients with multiple sclerosis in Hungary. <i>Ideggyogyaszati Szemle</i> , 2012, 65, 316-24.	0.4	7
95	Determinants of the acceptability of health problems in different ages: exploring a new application of the EQ VAS. <i>European Journal of Health Economics</i> , 2019, 20, 31-41.	1.4	6
96	Development of Population Tariffs for the CarerQol Instrument for Hungary, Poland and Slovenia: A Discrete Choice Experiment Study to Measure the Burden of Informal Caregiving. <i>Pharmacoeconomics</i> , 2020, 38, 633-643.	1.7	6
97	Validation of the Hungarian version of the CarerQol instrument in informal caregivers: results from a cross-sectional survey among the general population in Hungary. <i>Quality of Life Research</i> , 2021, 30, 629-641.	1.5	6
98	Development of Population Tariffs for the ICECAP-A Instrument for Hungary and their Comparison With the UK Tariffs. <i>Value in Health</i> , 2021, 24, 1845-1852.	0.1	6
99	Long-term costs and survival of prostate cancer: a population-based study. <i>International Urology and Nephrology</i> , 2017, 49, 1707-1714.	0.6	5
100	Patient and general population values for luminal and perianal fistulising Crohn's disease health states. <i>European Journal of Health Economics</i> , 2019, 20, 91-100.	1.4	5
101	Measuring the acceptability of EQ-5D-3L health states for different ages: a new adaptive survey methodology. <i>European Journal of Health Economics</i> , 2022, 23, 1243-1255.	1.4	5
102	Exploring the Relationship between Quality of Life (EQ-5D) and Clinical Measures in Adult Attention Deficit Hyperactivity Disorder (ADHD). <i>Applied Research in Quality of Life</i> , 2017, 12, 409-424.	1.4	4
103	Eliciting preferences for outpatient care experiences in Hungary: A discrete choice experiment with a national representative sample. <i>PLoS ONE</i> , 2020, 15, e0235165.	1.1	4
104	Comparing the measurement properties of the ICECAP-A and ICECAP-O instruments in ages 50-70: a cross-sectional study on a representative sample of the Hungarian general population. <i>European Journal of Health Economics</i> , 2021, 22, 1453-1466.	1.4	4
105	Comparing self-perceived and estimated fracture risk by FRAX® of women with osteoporosis. <i>Archives of Osteoporosis</i> , 2017, 12, 4.	1.0	3
106	Acceptable health and ageing: results of a cross-sectional study from Hungary. <i>Health and Quality of Life Outcomes</i> , 2020, 18, 346.	1.0	3
107	Self-Reported Waiting Times for Outpatient Health Care Services in Hungary: Results of a Cross-Sectional Survey on a National Representative Sample. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 2213.	1.2	3
108	Patient-reported outcomes: opportunities and challenges in Central Europe. <i>European Journal of Health Economics</i> , 2019, 20, 1-3.	1.4	2

#	ARTICLE	IF	CITATIONS
109	PNS197 WAITING TIMES FOR HEALTH CARE SERVICES IN HUNGARY - RESULTS OF A REPRESENTATIVE POPULATION SURVEY. Value in Health, 2019, 22, S794.	0.1	2
110	Subjective expectations regarding longevity and future health: a cross-sectional survey among patients with Crohn's disease. Colorectal Disease, 2021, 23, 105-113.	0.7	2
111	Editorial: Accelerated Globalization and Its Impact to the World's Health Care Achievement. Frontiers in Public Health, 2021, 9, 690239.	1.3	2
112	PNS32 Towards a Healthcare Cost Catalogue for Middle EAST and North Africa: A Systematic Review of Productivity Loss Costs Reported in Health Economic Publications between 1989-2019. Value in Health, 2020, 23, S649.	0.1	2
113	Patient experiences in a public primary health care clinic: A South African case study. Society and Economy, 2020, 42, 333-347.	0.2	2
114	QUALITY OF LIFE OF PATIENTS WITH NON-DIABETIC PERIPHERAL NEUROPATHIC PAIN; RESULTS FROM A CROSS-SECTIONAL SURVEY IN GENERAL PRACTICES IN HUNGARY. Ideggyszemle, 2015, 68, 325-30.	0.4	2
115	Comparing actuarial and subjective healthy life expectancy estimates: A cross-sectional survey among the general population in Hungary. PLoS ONE, 2022, 17, e0264708.	1.1	2
116	PMS3 - INFLIXIMAB FOR DISEASE-MODIFYING ANTI-RHEUMATIC DRUG-NAIVE RHEUMATOID ARTHRITIS PATIENTS: SYSTEMATIC REVIEW AND DESCRIPTIVE ANALYSIS OF PUBLICATIONS OF RANDOMIZED CONTROLLED TRIALS. Value in Health, 2018, 21, S288.	0.1	1
117	PNS331 QUANTIFYING THE ACCEPTABILITY OF HEALTH PROBLEMS IN DIFFERENT AGES USING THE EQ-5D-3L INSTRUMENT. Value in Health, 2019, 22, S820.	0.1	1
118	Costs of Infection Control and Special Challenges during the Covid-19 Pandemic: Experiences in a Military Hospital. Academic and Applied Research in Military and Public, 2021, 20, 95-110.	0.0	1
119	Musculoskeletal health and capability wellbeing: Associations between the HAQ-DI, ICECAP-A and ICECAP-O measures in a population survey. Musculoskeletal Science and Practice, 2021, 55, 102420.	0.6	1
120	PNS38 Towards a Healthcare Cost Catalogue for Middle EAST and North Africa: A Systematic Review of Costs Reported in Health Economic Publications from Jordan, Lebanon Palestine and Syria 1995-2019. Value in Health, 2020, 23, S650.	0.1	1
121	PNS20 Towards a Healthcare Cost Catalogue for Middle EAST and North Africa: A Systematic Review of Costs Reported in Health Economic Publications from Egypt 1995-2019. Value in Health, 2020, 23, S647.	0.1	1
122	PNS19 Towards a Healthcare Cost Catalogue for Middle EAST and North Africa: A Systematic Review of Costs Reported in Health Economic Publications from Algeria, Libya, Morocco and Tunisia 1995-2019. Value in Health, 2020, 23, S647.	0.1	1
123	PNS34 Towards a Healthcare Cost Catalogue for Middle EAST and North Africa: A Systematic Review of Costs Reported in Health Economic Publications from the GULF Region 1995-2019. Value in Health, 2020, 23, S649.	0.1	1
124	Patient-centred care in Hungary: Contributions to foster a policy agenda. Zeitschrift Fur Evidenz, Fortbildung Und Qualitat Im Gesundheitswesen, 2022, , .	0.7	1
125	Title is missing!. , 2020, 15, e0235165.		0
126	Title is missing!. , 2020, 15, e0235165.		0

#	ARTICLE	IF	CITATIONS
127	Title is missing!. , 2020, 15, e0235165.		0
128	Title is missing!. , 2020, 15, e0235165.		0
129	Title is missing!. , 2020, 15, e0235165.		0
130	Title is missing!. , 2020, 15, e0235165.		0